HomeCompareAWH vs QYLD

AWH vs QYLD: Dividend Comparison 2026

AWH yields 2439.02% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AWH wins by $63854957655.67M in total portfolio value
10 years
AWH
AWH
● Live price
2439.02%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63854957655.69M
Annual income
$59,089,222,446,113,760.00
Full AWH calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — AWH vs QYLD

📍 AWH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAWHQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AWH + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AWH pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AWH
Annual income on $10K today (after 15% tax)
$207,317.07/yr
After 10yr DRIP, annual income (after tax)
$50,225,839,079,196,696.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, AWH beats the other by $50,225,839,079,191,890.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AWH + QYLD for your $10,000?

AWH: 50%QYLD: 50%
100% QYLD50/50100% AWH
Portfolio after 10yr
$31927478827.86M
Annual income
$29,544,611,223,059,708.00/yr
Blended yield
92.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AWH right now

AWH
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Price Target
$3.30
+3924.4% upside vs current
Range: $3.30 — $3.30
Altman Z
-107.5
Piotroski
2/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AWH buys
0
QYLD buys
0
No recent congressional trades found for AWH or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAWHQYLD
Forward yield2439.02%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$63854957655.69M$25.4K
Annual income after 10y$59,089,222,446,113,760.00$5,659.31
Total dividends collected$63521423927.75M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AWH vs QYLD ($10,000, DRIP)

YearAWH PortfolioAWH Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$254,602$243,902.44$10,352$1,192.36+$244.3KAWH
2$6,075,991$5,803,565.97$10,830$1,347.57+$6.07MAWH
3$135,940,468$129,439,158.13$11,460$1,539.07+$135.93MAWH
4$2,851,990,824$2,706,534,523.24$12,275$1,777.84+$2851.98MAWH
5$56,119,194,681$53,067,564,499.36$13,323$2,078.95+$56119.18MAWH
6$1,035,955,104,440$975,907,566,131.16$14,667$2,463.34+$1035955.09MAWH
7$17,945,072,646,301$16,836,600,684,550.52$16,396$2,960.57+$17945072.63MAWH
8$291,769,260,867,746$272,568,033,136,203.20$18,631$3,612.97+$291769260.85MAWH
9$4,453,958,139,792,869$4,141,765,030,664,381.00$21,548$4,482.15+$4453958139.77MAWH
10$63,854,957,655,692,136$59,089,222,446,113,760.00$25,398$5,659.31+$63854957655.67MAWH

AWH vs QYLD: Complete Analysis 2026

AWHStock

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Full AWH Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this AWH vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AWH vs SCHDAWH vs JEPIAWH vs OAWH vs KOAWH vs MAINAWH vs XYLDAWH vs JEPQAWH vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.